The University of Chicago Header Logo

Connection

Kenneth S. Polonsky to Insulin

This is a "connection" page, showing publications Kenneth S. Polonsky has written about Insulin.
Connection Strength

9.321
  1. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012 Jul; 61(7):1793-800.
    View in: PubMed
    Score: 0.290
  2. Impaired insulin secretion in transgenic mice over-expressing calpastatin in pancreatic ß-cells. Islets. 2009 Nov-Dec; 1(3):242-8.
    View in: PubMed
    Score: 0.244
  3. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes. 2009 Aug; 58(8):1869-78.
    View in: PubMed
    Score: 0.238
  4. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19575-80.
    View in: PubMed
    Score: 0.200
  5. Suppressed insulin signaling and increased apoptosis in CD38-null islets. Diabetes. 2006 Oct; 55(10):2737-46.
    View in: PubMed
    Score: 0.197
  6. Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion. FASEB J. 2004 May; 18(7):878-80.
    View in: PubMed
    Score: 0.166
  7. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.162
  8. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab. 2004 Jan; 286(1):E41-9.
    View in: PubMed
    Score: 0.160
  9. Organ alchemy: producing insulin in the liver. Nat Med. 2003 May; 9(5):504-5.
    View in: PubMed
    Score: 0.156
  10. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
    View in: PubMed
    Score: 0.144
  11. Calpains play a role in insulin secretion and action. Diabetes. 2001 Sep; 50(9):2013-20.
    View in: PubMed
    Score: 0.139
  12. The pancreatic beta cell heats up: UCP2 and insulin secretion in diabetes. Cell. 2001 Jun 15; 105(6):705-7.
    View in: PubMed
    Score: 0.137
  13. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000 Aug; 106(3):329-33.
    View in: PubMed
    Score: 0.129
  14. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. 2000 Jun; 24 Suppl 2:S29-31.
    View in: PubMed
    Score: 0.127
  15. Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab. 2000 Feb; 278(2):E340-51.
    View in: PubMed
    Score: 0.124
  16. Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: role of enhanced fuel metabolism. Metabolism. 1999 Jul; 48(7):857-64.
    View in: PubMed
    Score: 0.119
  17. Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice. Diabetes. 1998 Dec; 47(12):1881-8.
    View in: PubMed
    Score: 0.115
  18. Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice. J Biol Chem. 1998 Sep 18; 273(38):24457-64.
    View in: PubMed
    Score: 0.113
  19. Apoptosis in insulin-secreting cells. Evidence for the role of intracellular Ca2+ stores and arachidonic acid metabolism. J Clin Invest. 1998 Apr 15; 101(8):1623-32.
    View in: PubMed
    Score: 0.110
  20. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998 Mar; 47(3):358-64.
    View in: PubMed
    Score: 0.109
  21. Temporal profiles and clinical significance of pulsatile insulin secretion. Horm Res. 1998; 49(3-4):178-84.
    View in: PubMed
    Score: 0.108
  22. Insulin production: from gene to granule. Diabetologia. 1997 Oct; 40 Suppl 3:B33-8.
    View in: PubMed
    Score: 0.106
  23. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.104
  24. Alternative insulin delivery systems: how demanding should the patient be? Diabetologia. 1997 Jul; 40 Suppl 2:S97-101.
    View in: PubMed
    Score: 0.104
  25. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.101
  26. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes. 1996 Nov; 45(11):1503-10.
    View in: PubMed
    Score: 0.099
  27. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol. 1996 Oct; 271(4 Pt 1):E742-7.
    View in: PubMed
    Score: 0.099
  28. Glucokinase mutations, insulin secretion, and diabetes mellitus. Annu Rev Physiol. 1996; 58:171-86.
    View in: PubMed
    Score: 0.094
  29. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am J Physiol. 1995 Oct; 269(4 Pt 1):E786-92.
    View in: PubMed
    Score: 0.092
  30. Insulin secretion in insulin-resistant women with a history of gestational diabetes. Metabolism. 1995 Aug; 44(8):1067-73.
    View in: PubMed
    Score: 0.091
  31. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.090
  32. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes. 1995 Jun; 44(6):699-704.
    View in: PubMed
    Score: 0.090
  33. Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 1995 Apr; 18(4):568-71.
    View in: PubMed
    Score: 0.089
  34. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol. 1995 Jan; 268(1 Pt 1):E21-7.
    View in: PubMed
    Score: 0.087
  35. Alterations in pulsatile insulin secretion in the Zucker diabetic fatty rat. Am J Physiol. 1994 Aug; 267(2 Pt 1):E250-9.
    View in: PubMed
    Score: 0.085
  36. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes. 1994 Jul; 43(7):871-7.
    View in: PubMed
    Score: 0.084
  37. Compensation in pancreatic beta-cell function in subjects with glucokinase mutations. Diabetes. 1994 May; 43(5):718-23.
    View in: PubMed
    Score: 0.083
  38. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 1993 Jul; 92(1):262-71.
    View in: PubMed
    Score: 0.079
  39. Quantitative evaluation of the effect of low-intensity exercise on insulin secretion in man. Metabolism. 1993 Jul; 42(7):829-33.
    View in: PubMed
    Score: 0.079
  40. Oscillatory insulin secretion after pancreas transplant. Diabetes. 1993 Jun; 42(6):855-61.
    View in: PubMed
    Score: 0.078
  41. Analytical problems in detecting rapid insulin secretory pulses in normal humans. Am J Physiol. 1993 Feb; 264(2 Pt 1):E231-8.
    View in: PubMed
    Score: 0.077
  42. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993 Jan; 76(1):44-8.
    View in: PubMed
    Score: 0.076
  43. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab. 1993 Jan; 76(1):79-84.
    View in: PubMed
    Score: 0.076
  44. The past 200 years in diabetes. N Engl J Med. 2012 Oct 04; 367(14):1332-40.
    View in: PubMed
    Score: 0.075
  45. Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. Am J Physiol. 1992 Apr; 262(4 Pt 1):E467-75.
    View in: PubMed
    Score: 0.072
  46. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 Mar; 41(3):368-77.
    View in: PubMed
    Score: 0.072
  47. Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. J Clin Invest. 1991 Sep; 88(3):934-42.
    View in: PubMed
    Score: 0.069
  48. Postprandial triglyceride response in type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement. Diabetologia. 1991 Apr; 34(4):253-9.
    View in: PubMed
    Score: 0.067
  49. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest. 1991 Feb; 87(2):439-45.
    View in: PubMed
    Score: 0.067
  50. Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med. 1990 Aug 20; 89(2A):11S-16S; discussion 51S-53S.
    View in: PubMed
    Score: 0.065
  51. Lack of effect of high-dose biosynthetic human C-peptide on pancreatic hormone release in normal subjects. Metabolism. 1990 Aug; 39(8):827-32.
    View in: PubMed
    Score: 0.064
  52. Hypoglycemic thresholds for cognitive dysfunction in humans. Diabetes. 1990 Jul; 39(7):828-35.
    View in: PubMed
    Score: 0.064
  53. Effect of temporal distribution of calories on diurnal patterns of glucose levels and insulin secretion in NIDDM. Diabetes Care. 1990 Jul; 13(7):748-55.
    View in: PubMed
    Score: 0.064
  54. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J Biol Chem. 2010 Jun 25; 285(26):19842-53.
    View in: PubMed
    Score: 0.063
  55. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010 Feb; 59(2):479-85.
    View in: PubMed
    Score: 0.061
  56. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1989 Sep; 69(3):571-6.
    View in: PubMed
    Score: 0.060
  57. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009 Apr; 9(4):350-61.
    View in: PubMed
    Score: 0.059
  58. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab. 1988 Nov; 67(5):1094-9.
    View in: PubMed
    Score: 0.057
  59. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes. 1988 Oct; 37(10):1351-7.
    View in: PubMed
    Score: 0.057
  60. Reevaluation of urine C-peptide as measure of insulin secretion. Diabetes. 1988 Sep; 37(9):1195-201.
    View in: PubMed
    Score: 0.056
  61. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 May 12; 318(19):1231-9.
    View in: PubMed
    Score: 0.055
  62. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.
    View in: PubMed
    Score: 0.054
  63. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):435-41.
    View in: PubMed
    Score: 0.054
  64. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):442-8.
    View in: PubMed
    Score: 0.054
  65. Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes. 1987 Dec; 36(12):1365-71.
    View in: PubMed
    Score: 0.054
  66. Calculated pattern of intraportal insulin appearance without independent assessment of C-peptide kinetics. Diabetes. 1987 Oct; 36(10):1195-202.
    View in: PubMed
    Score: 0.053
  67. Insulin Wakayama: familial mutant insulin syndrome in Japan. Diabetologia. 1987 Feb; 30(2):87-92.
    View in: PubMed
    Score: 0.051
  68. A significant role for histocompatibility in human islet transplantation. Transplantation. 2006 Jul 27; 82(2):180-7.
    View in: PubMed
    Score: 0.049
  69. Calculation of the systemic delivery rate of insulin in normal man. J Clin Endocrinol Metab. 1986 Jul; 63(1):113-8.
    View in: PubMed
    Score: 0.048
  70. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986 Apr; 35(4):379-86.
    View in: PubMed
    Score: 0.048
  71. Ca2+ controls slow NAD(P)H oscillations in glucose-stimulated mouse pancreatic islets. J Physiol. 2006 Apr 15; 572(Pt 2):379-92.
    View in: PubMed
    Score: 0.047
  72. Mutant insulin syndrome: identification of two families with [LeuA3]insulin and determination of its biological activity. Trans Assoc Am Physicians. 1986; 99:132-42.
    View in: PubMed
    Score: 0.047
  73. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.
    View in: PubMed
    Score: 0.047
  74. Current approaches to measurement of insulin secretion. Diabetes Metab Rev. 1986; 2(3-4):315-29.
    View in: PubMed
    Score: 0.047
  75. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005 Nov; 54(11):3265-73.
    View in: PubMed
    Score: 0.046
  76. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes. 2005 Aug; 54(8):2447-52.
    View in: PubMed
    Score: 0.046
  77. Diabetic pancreatic beta cells ARNT all they should be. Cell Metab. 2005 Aug; 2(2):78-80.
    View in: PubMed
    Score: 0.046
  78. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab. 2005 Dec; 289(6):E954-9.
    View in: PubMed
    Score: 0.045
  79. Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion. J Biol Chem. 2005 Feb 11; 280(6):4992-5003.
    View in: PubMed
    Score: 0.043
  80. Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes. 1984 Nov; 33(11):1112-9.
    View in: PubMed
    Score: 0.043
  81. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest. 1984 Nov; 74(5):1821-9.
    View in: PubMed
    Score: 0.043
  82. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J Clin Invest. 2004 Oct; 114(7):928-36.
    View in: PubMed
    Score: 0.043
  83. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1984 May; 33(5):486-94.
    View in: PubMed
    Score: 0.042
  84. A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metabolism. 2003 May; 52(5):528-34.
    View in: PubMed
    Score: 0.039
  85. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest. 2003 Apr; 111(8):1147-60.
    View in: PubMed
    Score: 0.039
  86. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol (Copenh). 1983 Mar; 102(3):420-7.
    View in: PubMed
    Score: 0.038
  87. Glucose ingestion in dogs alters the hepatic extraction of insulin. In vivo evidence for a relationship between biologic action and extraction of insulin. J Clin Invest. 1982 Mar; 69(3):516-25.
    View in: PubMed
    Score: 0.036
  88. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes. 2002 Feb; 51 Suppl 1:S227-33.
    View in: PubMed
    Score: 0.036
  89. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature. 2001 Dec 13; 414(6865):788-91.
    View in: PubMed
    Score: 0.035
  90. Insulin and glucagon breakthrough of somatostatin suppression: importance of portal vein hormone measurements. Diabetes. 1981 Aug; 30(8):664-9.
    View in: PubMed
    Score: 0.034
  91. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab. 2001 Aug; 281(2):E242-7.
    View in: PubMed
    Score: 0.034
  92. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes. 2001 Aug; 50(8):1828-33.
    View in: PubMed
    Score: 0.034
  93. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001 Feb; 50(2):322-8.
    View in: PubMed
    Score: 0.033
  94. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
    View in: PubMed
    Score: 0.033
  95. Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of Langerhans. Metabolism. 2000 Dec; 49(12):1579-87.
    View in: PubMed
    Score: 0.033
  96. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes. 2000 Aug; 49(8):1334-40.
    View in: PubMed
    Score: 0.032
  97. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab. 2000 Mar; 278(3):E501-8.
    View in: PubMed
    Score: 0.031
  98. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999 Sep; 84(9):3082-92.
    View in: PubMed
    Score: 0.030
  99. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 1999 May; 48(5):989-96.
    View in: PubMed
    Score: 0.030
  100. Free fatty acids impair hepatic insulin extraction in vivo. Diabetes. 1999 Apr; 48(4):766-74.
    View in: PubMed
    Score: 0.029
  101. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes. 1999; 107 Suppl 4:S124-7.
    View in: PubMed
    Score: 0.029
  102. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest. 1998 May 15; 101(10):2215-22.
    View in: PubMed
    Score: 0.028
  103. Insulin acutely suppresses glucose production by both peripheral and hepatic effects in normal dogs. Am J Physiol. 1998 02; 274(2):E346-56.
    View in: PubMed
    Score: 0.027
  104. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene. Diabetes. 1997 Nov; 46(11):1749-54.
    View in: PubMed
    Score: 0.027
  105. Evidence that insulin can directly inhibit hepatic glucose production. Diabetologia. 1997 Nov; 40(11):1300-6.
    View in: PubMed
    Score: 0.027
  106. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab. 1997 Jun; 82(6):1834-8.
    View in: PubMed
    Score: 0.026
  107. A novel point mutation in the insulin gene giving rise to hyperproinsulinemia. J Clin Endocrinol Metab. 1997 May; 82(5):1629-31.
    View in: PubMed
    Score: 0.026
  108. Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats. Diabetes. 1996 Nov; 45(11):1626-30.
    View in: PubMed
    Score: 0.025
  109. Diurnal variations in cardiovascular function and glucose regulation in normotensive humans. Hypertension. 1996 Nov; 28(5):863-71.
    View in: PubMed
    Score: 0.025
  110. Maturity onset diabetes of the young (MODY). Diabet Med. 1996 Sep; 13(9 Suppl 6):S90-5.
    View in: PubMed
    Score: 0.025
  111. Abnormalities of insulin pulsatility and glucose oscillations during meals in obese noninsulin-dependent diabetic patients: effects of weight reduction. J Clin Endocrinol Metab. 1996 Jun; 81(6):2061-8.
    View in: PubMed
    Score: 0.024
  112. Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Diabetologia. 1996 May; 39(5):564-72.
    View in: PubMed
    Score: 0.024
  113. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. J Vet Intern Med. 1996 May-Jun; 10(3):116-22.
    View in: PubMed
    Score: 0.024
  114. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes. 1996 Apr; 45(4):478-87.
    View in: PubMed
    Score: 0.024
  115. Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function. Am J Physiol. 1996 Apr; 270(4 Pt 1):E572-9.
    View in: PubMed
    Score: 0.024
  116. Preservation of insulin secretory responses to P2 purinoceptor agonists in Zucker diabetic fatty rats. Am J Physiol. 1996 Mar; 270(3 Pt 1):E504-12.
    View in: PubMed
    Score: 0.024
  117. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes. 1996 Feb; 45(2):242-56.
    View in: PubMed
    Score: 0.024
  118. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996 Jan; 270(1 Pt 1):E36-42.
    View in: PubMed
    Score: 0.023
  119. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995 Jun; 44(6):705-17.
    View in: PubMed
    Score: 0.022
  120. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes. 1995 May; 44(5):506-12.
    View in: PubMed
    Score: 0.022
  121. 24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations. J Clin Invest. 1995 Apr; 95(4):1464-71.
    View in: PubMed
    Score: 0.022
  122. Reduced levels of messenger ribonucleic acid for calcium channel, glucose transporter-2, and glucokinase are associated with alterations in insulin secretion in fasted rats. Endocrinology. 1994 Sep; 135(3):1010-7.
    View in: PubMed
    Score: 0.021
  123. A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide versus insulin infusion. J Clin Endocrinol Metab. 1994 Jul; 79(1):66-70.
    View in: PubMed
    Score: 0.021
  124. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes. 1994 Jan; 43(1):40-6.
    View in: PubMed
    Score: 0.020
  125. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15; 306(4):G301-9.
    View in: PubMed
    Score: 0.020
  126. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Nov; 77(5):1287-93.
    View in: PubMed
    Score: 0.020
  127. Expression of calcium channel mRNAs in rat pancreatic islets and downregulation after glucose infusion. Diabetes. 1993 Jul; 42(7):948-55.
    View in: PubMed
    Score: 0.020
  128. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.019
  129. Differential effects of glucose stimulation upon rapid pulses and ultradian oscillations of insulin secretion. J Clin Endocrinol Metab. 1993 Apr; 76(4):895-901.
    View in: PubMed
    Score: 0.019
  130. Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes. 1992 Oct; 41(10):1346-54.
    View in: PubMed
    Score: 0.019
  131. Role of basal triglyceride and high density lipoprotein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab. 1992 Aug; 75(2):465-71.
    View in: PubMed
    Score: 0.018
  132. Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1992 Jul; 35(7):681-9.
    View in: PubMed
    Score: 0.018
  133. A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto). J Clin Invest. 1992 Jun; 89(6):1902-7.
    View in: PubMed
    Score: 0.018
  134. Ginsenoside Re rapidly reverses insulin resistance in muscles of high-fat diet fed rats. Metabolism. 2012 Nov; 61(11):1615-21.
    View in: PubMed
    Score: 0.018
  135. A practical approach to fasting hypoglycemia. N Engl J Med. 1992 Apr 09; 326(15):1020-1.
    View in: PubMed
    Score: 0.018
  136. Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes. 1992 Mar; 41(3):392-9.
    View in: PubMed
    Score: 0.018
  137. Persistence of oscillatory insulin secretion in denervated islet cell autografts. Transplantation. 1991 Sep; 52(3):574-6.
    View in: PubMed
    Score: 0.017
  138. Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography. Diabetes Care. 1991 Jul; 14(7):544-7.
    View in: PubMed
    Score: 0.017
  139. Computer model for mechanisms underlying ultradian oscillations of insulin and glucose. Am J Physiol. 1991 May; 260(5 Pt 1):E801-9.
    View in: PubMed
    Score: 0.017
  140. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab. 1991 Apr; 72(4):934-44.
    View in: PubMed
    Score: 0.017
  141. Does tight glucose control enhance brain sensitivity to low glucose? Diabetes Care. 1991 Feb; 14(2):141-3.
    View in: PubMed
    Score: 0.017
  142. Effects of insulin mediated plasma glucose changes on brain function. Implications from experimental and derived data. Acta Radiol Suppl. 1991; 376:161-2.
    View in: PubMed
    Score: 0.017
  143. Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites. Endocrinology. 1990 Nov; 127(5):2418-22.
    View in: PubMed
    Score: 0.016
  144. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1990 Jun; 70(6):1594-602.
    View in: PubMed
    Score: 0.016
  145. Pattern of postprandial carbohydrate metabolism and effects of portal and peripheral insulin delivery. Diabetes. 1990 Feb; 39(2):142-8.
    View in: PubMed
    Score: 0.016
  146. Change in hexose distribution volume and fractional utilization of [18F]-2-deoxy-2-fluoro-D-glucose in brain during acute hypoglycemia in humans. Diabetes. 1990 Feb; 39(2):175-80.
    View in: PubMed
    Score: 0.016
  147. Effects of aging on insulin secretion. Diabetes. 1989 Dec; 38(12):1549-56.
    View in: PubMed
    Score: 0.015
  148. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.015
  149. Role of HNF-1alpha in regulating the expression of genes involved in cellular growth and proliferation in pancreatic beta-cells. Diabetes Res Clin Pract. 2009 Apr; 84(1):19-26.
    View in: PubMed
    Score: 0.015
  150. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab. 1988 Aug; 67(2):307-14.
    View in: PubMed
    Score: 0.014
  151. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity (Silver Spring). 2008 Jun; 16(6):1349-54.
    View in: PubMed
    Score: 0.014
  152. Sustained expression of hepatocyte nuclear factor-6 leads to loss of pancreatic beta-cells by apoptosis. Exp Clin Endocrinol Diabetes. 2007 Nov; 115(10):654-61.
    View in: PubMed
    Score: 0.013
  153. Lack of direct inhibition of insulin secretion by exogenous insulin in the canine pancreas. J Clin Invest. 1986 Nov; 78(5):1193-8.
    View in: PubMed
    Score: 0.012
  154. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30.
    View in: PubMed
    Score: 0.012
  155. Long-term follow-up of canine segmental pancreatic autografts. Diabetes. 1985 Feb; 34(2):174-8.
    View in: PubMed
    Score: 0.011
  156. Pancreatic hormone profiles and metabolism posthepatectomy in the dog. Evidence for a hepatotrophic role of insulin, glucagon, and pancreatic polypeptide. Gastroenterology. 1984 Sep; 87(3):679-87.
    View in: PubMed
    Score: 0.011
  157. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med. 1984 May 17; 310(20):1288-94.
    View in: PubMed
    Score: 0.010
  158. Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model. J Clin Invest. 1984 May; 73(5):1351-8.
    View in: PubMed
    Score: 0.010
  159. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003 Nov; 112(10):1550-60.
    View in: PubMed
    Score: 0.010
  160. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest. 1983 Sep; 72(3):1114-23.
    View in: PubMed
    Score: 0.010
  161. Responses of somatostatin components to oral glucose in human plasma. Trans Assoc Am Physicians. 1983; 96:113-21.
    View in: PubMed
    Score: 0.010
  162. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002 Jun; 51(6):1851-8.
    View in: PubMed
    Score: 0.009
  163. Surface receptors for pancreatic hormones in dog and rat hepatocytes: qualitative and quantitative differences in hormone-target cell interactions. Proc Natl Acad Sci U S A. 1982 Apr; 79(7):2167-71.
    View in: PubMed
    Score: 0.009
  164. Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes. 2001 Nov; 50(11):2472-80.
    View in: PubMed
    Score: 0.009
  165. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 1981 Mar; 240(3):E233-44.
    View in: PubMed
    Score: 0.008
  166. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001 Jan; 50(1):150-8.
    View in: PubMed
    Score: 0.008
  167. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes. 1998 Aug; 47(8):1259-65.
    View in: PubMed
    Score: 0.007
  168. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Feb 01; 128(3):176-85.
    View in: PubMed
    Score: 0.007
  169. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes. Diabetes. 1997 Sep; 46(9):1434-9.
    View in: PubMed
    Score: 0.007
  170. Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotally gastrectomized patient. Eur J Endocrinol. 1997 Jan; 136(1):96-9.
    View in: PubMed
    Score: 0.006
  171. Ultradian oscillations of leptin secretion in humans. Biochem Biophys Res Commun. 1996 Nov 21; 228(3):733-8.
    View in: PubMed
    Score: 0.006
  172. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995 Dec; 44(12):1447-57.
    View in: PubMed
    Score: 0.006
  173. Effects of aging on glucose regulation during wakefulness and sleep. Am J Physiol. 1995 Dec; 269(6 Pt 1):E1006-16.
    View in: PubMed
    Score: 0.006
  174. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med. 1995 Nov 23; 333(21):1386-90.
    View in: PubMed
    Score: 0.006
  175. Abnormal temporal patterns of glucose tolerance in obesity: relationship to sleep-related growth hormone secretion and circadian cortisol rhythmicity. J Clin Endocrinol Metab. 1994 Dec; 79(6):1797-805.
    View in: PubMed
    Score: 0.005
  176. Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Jul; 77(1):6-10.
    View in: PubMed
    Score: 0.005
  177. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab. 1991 Feb; 72(2):444-54.
    View in: PubMed
    Score: 0.004
  178. The effect of a time delay on the characteristics of the canine glucoregulatory system. Metabolism. 1990 Dec; 39(12):1219-24.
    View in: PubMed
    Score: 0.004
  179. The effect of biosynthetic human proinsulin on the hepatic response to glucagon in insulin-deficient diabetes. J Clin Endocrinol Metab. 1987 Mar; 64(3):476-81.
    View in: PubMed
    Score: 0.003
  180. Natural history of intrahepatic canine islet cell autografts. J Clin Invest. 1986 Nov; 78(5):1339-48.
    View in: PubMed
    Score: 0.003
  181. In vivo pulsatility of pancreatic islet peptides. Am J Physiol. 1986 Aug; 251(2 Pt 1):E215-26.
    View in: PubMed
    Score: 0.003
  182. The measurement and validation of the nonsteady-state rates of C-peptide appearance in the dog. Diabetologia. 1986 Jul; 29(7):440-6.
    View in: PubMed
    Score: 0.003
  183. Variable deterioration in cortical function during insulin-induced hypoglycemia. Diabetes. 1985 Jul; 34(7):677-85.
    View in: PubMed
    Score: 0.003
  184. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984 Aug; 33(8):762-70.
    View in: PubMed
    Score: 0.003
  185. The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. J Clin Endocrinol Metab. 1984 Jun; 58(6):973-9.
    View in: PubMed
    Score: 0.003
  186. A familial glucagonoma syndrome: genetic, clinical and biochemical features. Am J Med. 1981 May; 70(5):1017-26.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.